Revvity, Inc. research snapshot
RVTY AI stock analysis reads Revvity, Inc. as a focused life sciences and diagnostics platform with improving organic growth, strong cash generation, and a cleaner portfolio after the planned China Immunodiagnostics divestiture. At the August 2, 2026 data cutoff, RVTY closed at $112.52 on July 31, 2026 with a market capitalization near $12.55 billion, and the next earnings report is scheduled for August 4, 2026 before the market opens. The analysis is constructive on the business but cautious on valuation and margin timing because GAAP earnings remain low, net debt is near $2.49 billion, and the stock trades just below resistance. This page is informational only and not investment advice.
Current price
$112.52
Market cap
$12.55 billion
AI score
70 / 100
Rating
Improving health science platform with a premium valuation and margin watch
Trend status
Uptrend above the 50-day and 200-day moving averages, near resistance ahead of August 4 earnings
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Revvity sells reagents, instruments, software, services, reproductive health tests, newborn screening, and immunodiagnostics used in drug discovery, genomics, imaging, and diagnostic workflows. | High |
| Moat | The moat comes from workflow integration, regulated diagnostic relationships, installed instruments, repeat consumables, software, and customer validation costs, but scale is smaller than Danaher or Thermo Fisher. | Medium-high |
| Management | CEO Prahlad Singh has led the portfolio repositioning, share repurchases, and the planned China Immunodiagnostics divestiture, which represented about 6% of fiscal 2025 revenue; execution is visible but still being tested. | Medium-high |
| Financial trend | Fiscal 2025 revenue rose 3.7% to $2.856 billion, Q1 2026 revenue rose 7% with 3% organic and 6% pro forma organic growth, and free cash flow stayed healthy near $493 million TTM, while adjusted margins compressed year over year. | High |
| Valuation | At about 53.9x trailing GAAP EPS, 20.5x forward EPS, and 25.5x free cash flow, the stock needs sustained growth and margin recovery to justify a large re-rating. | Medium-high |
| Technical trend | RVTY closed at $112.52 on July 31, 2026, up 17.37% since the May 19 buy candidate signal, but it trades just below accumulated-volume resistance near $112.95 to $113.54 ahead of August 4 earnings. | Medium |
| Risk level | Risk is medium. Main risks are life science funding cycles, diagnostic demand, China divestiture execution and timing, debt, tariff and mix pressure, the pending earnings print, and valuation sensitivity. | Medium-high |
| AI confidence | High confidence for reported financial facts, current price, and technical levels; lower confidence for adjusted margin timing and end-market recovery speed. | High data confidence |
| Investment certainty | Medium certainty because business quality is real, but the current price leaves less room for weak organic growth or another margin setback. | Medium |
RVTY AI stock forecast
The RVTY AI stock forecast uses scenario ranges rather than a point prediction. The valuation model indicates a wide three-year range because small changes in pro forma adjusted EPS growth and the exit multiple have a large effect on value, and the August 4, 2026 earnings report can shift the setup quickly.
$135 to $165
More likely if pro forma organic growth holds above 4%, adjusted margins recover toward prior levels, the China divestiture completes and supports buybacks and targeted acquisitions, and the market keeps RVTY near a premium life science tools multiple.
$110 to $125
More likely if pro forma adjusted EPS grows in the low to mid single digits, the forward multiple stays near 20x, and cash flow supports buybacks without major balance sheet strain, roughly in line with the analyst consensus near $117.
$80 to $95
More likely if life science customer budgets weaken, diagnostics growth slows, tariffs or mix keep margins under pressure, China divestiture timing slips, or investors value RVTY closer to a slower-growth diagnostics peer.
RVTY AI technical analysis
RVTY AI technical analysis uses the July 31, 2026 close of $112.52 because this static page does not fetch request-time chart data. The stock is in a rising trend above its 50-day and 200-day moving averages, but it sits just below accumulated-volume resistance with a possible swing of about 5.95% around the August 4, 2026 earnings release.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $112.52 | Closing price reported for July 31, 2026 and used as the technical data cutoff. |
| Near resistance | $112.95 to $113.54 | Accumulated-volume resistance was clustered just above the latest close, with Fibonacci resistance at $113.66 to $115.54. |
| Breakout reference | $113.66 to $115.54 | A move through this zone would suggest the short-term trend is extending rather than stalling. |
| Volume support | $111.21, then $101.22 and $99.09 | Accumulated-volume support sat at $111.21 just below price, with deeper support near $101.22 and $99.09. |
| Moving average support | $111.81 and $108.75 | StockInvest reported support lines from short and long-term moving averages that could hold on pullbacks. |
| Long-term trend reference | 200-day moving average near $98.92 | Price stayed well above the 200-day average, which kept the broader trend signal constructive. |
| Momentum | Positive with mixed signals | RSI was near 55.98, the stock rose 2.15% over two weeks, buy signals came from short and long-term averages, but a July 2 pivot top sell signal and a 3-month MACD sell signal were also active. |
| Volume | Fell on the last trading day | About 952 thousand shares traded on July 31 versus a 20-day average near 1.33 million, which can reduce conviction in the recent move. |
| Volatility | Medium, 3.27% one-week average daily move | The 14-day average true range implied a possible trading band near $110.63 to $114.41 on the next session. |
| Invalidation | Sustained close below $111.21 | A break below the first support cluster, and then below the $108.75 moving average support, would weaken the current uptrend setup. |
RVTY AI trading strategy
The RVTY AI trading strategy is a rules-based framework, not a personalized instruction. It should be paired with position sizing, awareness of the August 4, 2026 earnings date, and a written invalidation level.
Wait for RVTY to clear accumulated-volume resistance near $112.95 to $113.54 with volume confirmation and a stable reaction to the August 4, 2026 earnings release.
Reduce confidence if the breakout fails quickly or if price closes back below the $111.81 moving average support after earnings-related news.
If RVTY pulls back toward $108 to $111 without a change in fundamentals, review whether moving average support and the $111.21 volume support are still holding.
Do not average down below support unless the Q2 2026 earnings setup, guidance, and China divestiture details have been updated.
Track pro forma organic growth, adjusted operating margin, free cash flow, debt reduction, share count, and segment mix in Life Sciences and Diagnostics.
Reset valuation if pro forma adjusted EPS guidance moves below the $5.20 to $5.30 range or if free cash flow weakens while net debt stays near $2.5 billion.
Investment research summary
Revvity helps researchers, biopharma companies, labs, and healthcare systems run specialized discovery and diagnostic workflows through instruments, reagents, software, testing content, and services.
The moat is based on workflow know-how, regulated customer validation, installed instruments, repeat consumables, diagnostics relationships, and software, but the company competes against larger and well-funded platforms.
The thesis can fail if customers delay life science spending, the China Immunodiagnostics divestiture value or timing disappoints, debt limits flexibility, adjusted margins keep compressing, or adjusted earnings prove less cash-backed than recent results suggest.
Management has reshaped the former PerkinElmer portfolio toward Life Sciences and Diagnostics, announced the China Immunodiagnostics divestiture, and used buybacks while trying to restore organic growth and margin quality.
Drug discovery, genomics, reproductive health, newborn screening, and diagnostic automation remain long-duration health science trends, and the Signals software push into AI-assisted workflows is a positive innovation vector, but funding and purchasing cycles can be uneven.
The current price implies confidence in low to mid single digit organic growth and adjusted margin recovery. Margin of safety is limited if GAAP EPS stays low or the forward multiple compresses.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| RVTY price | $112.52 at the July 31, 2026 close | StockInvest.us RVTY technical snapshot | August 2, 2026 |
| Market capitalization | $12.55 billion, verified with financial_rigor.py using $112.52 and 111.56 million shares at 0.02% variance | StockInvest.us quote and StockAnalysis statistics | August 2, 2026 |
| Shares outstanding | 111.56 million, down 6.14% year over year, with institutional ownership near 98.67% | StockAnalysis statistics | August 2, 2026 |
| Fiscal 2025 revenue | $2.856 billion, up 3.7% from fiscal 2024 | Revvity FY2025 earnings release and StockAnalysis financials | August 2, 2026 |
| Q1 2026 revenue | $711 million reported revenue, 7% growth, 3% organic growth, and 6% pro forma organic growth | Revvity Q1 2026 earnings release | August 2, 2026 |
| FY2026 pro forma guidance | $2.81 billion to $2.84 billion revenue, 3% to 4% pro forma organic growth, and $5.20 to $5.30 pro forma adjusted EPS | Revvity Q1 2026 earnings release | August 2, 2026 |
| Cash and debt | $860.32 million cash and equivalents, $3.35 billion total debt, and $2.49 billion net debt at the April 5, 2026 balance sheet | StockAnalysis balance sheet | August 2, 2026 |
| Free cash flow | $509.41 million in fiscal 2025 and $492.69 million TTM | StockAnalysis income statement and cash flow | August 2, 2026 |
| Valuation | 53.87x trailing GAAP EPS, 20.51x forward EPS, 4.32x sales, and 25.48x free cash flow | StockAnalysis statistics | August 2, 2026 |
| Analyst consensus | Buy rating from 17 analysts with an average price target of $117.13, a low of $90, and a high of $145 | StockAnalysis forecast and ratings | August 2, 2026 |
| Technical levels | Resistance near $112.95 to $113.54, support near $111.21, $101.22, and $99.09, and a 52-week range of $81.22 to $118.30 | StockInvest.us RVTY technical snapshot | August 2, 2026 |
This RVTY AI stock analysis is an informational research tool only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast scenarios are based on available public data as of August 2, 2026 and can be wrong if earnings, guidance, interest rates, industry demand, or market conditions change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
